Fig. 2
Cumulative exposure to CZP per region or country in clinical trial and post-marketing TB analysis. a Pooled clinical trial CZP exposure Asia-Pacific: Australia, Hong Kong, New Zealand, Republic of Korea, Singapore; eastern Europe: Belarus, Croatia, Georgia, Romania, Russia, Serbia, Ukraine; central Europe: Bulgaria, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Poland, Slovakia, Slovenia; western Europe: Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK; North America: Canada, US; Latin America: Argentina, Brazil, Chile, Colombia. CZP, certolizumab pegol; PY, patient-years; TB: tuberculosis. b Post-marketing CZP exposure to 6 March 2015 (TB cut-off date) Asia-Pacific: Australia, Hong Kong, Malaysia, New Caledonia, Republic of Korea; eastern Europe: Romania, Russia; central Europe: Bulgaria, Czech Republic, Hungary, Poland, Slovakia, Slovenia; western Europe: Andorra, Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, UK; North America: Canada, US; Latin America: Argentina, Brazil, Chile, Colombia, Ecuador, French Guiana, Guadeloupe, Peru, Reunion; rest of the world: Bahrain, Cyprus, Egypt, Kuwait, Lebanon, Libya, Martinique, Qatar, Saudi Arabia, Turkey, UAE. CZP, certolizumab pegol; PY, patient-years; TB, tuberculosis